Scalper1 News
Juno Therapeutics (JUNO), which set a record as the most highly valued biotech IPO of 2014, reported fourth quarter earnings late Wednesday that missed Wall Street estimates by a wide margin. Juno is developing cellular immunotherapies to treat leukemia and lymphoma. It uses human T-cells as therapeutics to recognize and kill cancer cells. The company says that its technology has the potential to revolutionize the way cancer is treated. Juno Scalper1 News
Scalper1 News